News

cultivate(MD) Capital Funds LP Announces Investment into Nanochon

cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator.

Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration.  Nanochon’s Chondrograft™ replaces lost or damaged cartilage and encourages new growth using an innovative material and 3D printed designs that are cost-effective and easy to deploy treatment options.

R. Sean Churchill, MD, MBA, Managing Director of cultivate(MD) said, “cultivate(MD) is proud to announce their investment in the Series Seed Prime round for Nanochon. Over the past six years, cultivate(MD) Capital Funds has focused our efforts to help develop emerging technology that solves previously unsolvable healthcare conditions.  Nanochon fits this description perfectly as they address focal cartilage defects in the 18-55 year old active patient population.  Their novel implant has demonstrated unparalleled results in numerous equine studies and is in final preparation for first-in-human trials.  cultivate(MD) is proud to partner with Nanochon to help bring this technology to the forefront, and I am pleased to have been appointed to serve on Nanochon’s Board of Directors to represent cultivate(MD) Capital.

Benjamin Holmes, PhD, CEO of Nanochon said, “We at Nanochon are thrilled to welcome cultivate(MD) as a key investor and valued member of our Board of Directors. Their investment and board participation represent a significant vote of confidence in our vision and technology. This collaboration is a crucial step towards accelerating our groundbreaking work in revolutionizing joint health and regenerative treatments and will enable us to establish a new standard in minimally invasive, durable, and restorative treatments.”

 

Learn more here.

Recent News

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals

04/22/2025

ATCC Announces New Executive Leadership Appointments

ATCC, the world’s premier biological materials management and standards organization, today announced several new leadership appointments. Rebecca Bradford, MBA, has been promoted to the role of senior vice president of Government Programs, ATCC Federal Solutions (AFS); Manoj Menon, PhD, has joined the company as chief operating officer; and Rupali Lach was appointed vice president of Commercial Operations.